Community Research and Development Information Service - CORDIS

Abstract

A total of 620 projects were funded under the Biomedical and health research programme (1994-98). On the initiative of the European Commission, an impact assessment of the results of the programme was established. A programme review board consisting of 12 international experts from different (bio)medical disciplines performed this assessment. This publication contains the conclusions and recommendations of the board in relation to this programme.

The legal mandate of the board was to identify and assess:

- The programme's impact on the research communities involved and on the users.
- The impact on potential beneficiaries of research.
- The European added value of the programme and to suggest lessons to be learned for future programmes.

The opinion of the board was that research projects representing cutting edge research were present in all areas. They were especially present in pharmaceuticals research, brain research, cancer research, research on cardiovascular diseases and human genome research.

In conclusion, BIOMED 2 provided a very important transitional phase for introducing European medical research as an additional model to national research. It improved the quality of European research by generating the critical mass of knowledge both in clinical and basic research. It also prepared the concept of a European research area, which is currently being discussed.

Additional information

Authors: European Commission, ;Research DG,
Bibliographic Reference: EUR-OP, 2002, pp.328. Euro: 47.50
Availability: EUR-OP reference: KI-41-01-066-EN-C Available from EUR-OP sales agents. URL: http://eur-op.eu
ISBN: ISBN: 92-828-6716-1
Record Number: 200214833 / Last updated on: 2002-06-07
Category: PUBLICATION
Original language: en
Available languages: en